AU6000900A - Carbazole derivatives and their use as neuropeptide y5 receptor ligands - Google Patents

Carbazole derivatives and their use as neuropeptide y5 receptor ligands

Info

Publication number
AU6000900A
AU6000900A AU60009/00A AU6000900A AU6000900A AU 6000900 A AU6000900 A AU 6000900A AU 60009/00 A AU60009/00 A AU 60009/00A AU 6000900 A AU6000900 A AU 6000900A AU 6000900 A AU6000900 A AU 6000900A
Authority
AU
Australia
Prior art keywords
neuropeptide
receptor ligands
carbazole derivatives
carbazole
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU60009/00A
Inventor
Michael Howard Block
Samuel Craig Donald
Kevin Foote
Peter Robert Marsham
Paul Schofield
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca UK Ltd
Original Assignee
AstraZeneca UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9917173.8A external-priority patent/GB9917173D0/en
Priority claimed from GBGB9918380.8A external-priority patent/GB9918380D0/en
Priority claimed from GBGB9930314.1A external-priority patent/GB9930314D0/en
Application filed by AstraZeneca UK Ltd filed Critical AstraZeneca UK Ltd
Publication of AU6000900A publication Critical patent/AU6000900A/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/80[b, c]- or [b, d]-condensed
    • C07D209/82Carbazoles; Hydrogenated carbazoles
    • C07D209/88Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Child & Adolescent Psychology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU60009/00A 1999-07-23 2000-07-15 Carbazole derivatives and their use as neuropeptide y5 receptor ligands Abandoned AU6000900A (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB9917173 1999-07-23
GBGB9917173.8A GB9917173D0 (en) 1999-07-23 1999-07-23 Chemical compounds
GBGB9918380.8A GB9918380D0 (en) 1999-08-05 1999-08-05 Chemical compounds
GB9918380 1999-08-05
GBGB9930314.1A GB9930314D0 (en) 1999-12-22 1999-12-22 Chemical compounds
GB9930314 1999-12-22
PCT/GB2000/002745 WO2001007409A1 (en) 1999-07-23 2000-07-15 Carbazole derivatives and their use as neuropeptide y5 receptor ligands

Publications (1)

Publication Number Publication Date
AU6000900A true AU6000900A (en) 2001-02-13

Family

ID=27269782

Family Applications (1)

Application Number Title Priority Date Filing Date
AU60009/00A Abandoned AU6000900A (en) 1999-07-23 2000-07-15 Carbazole derivatives and their use as neuropeptide y5 receptor ligands

Country Status (2)

Country Link
AU (1) AU6000900A (en)
WO (1) WO2001007409A1 (en)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399631B1 (en) 1999-07-23 2002-06-04 Pfizer Inc. Carbazole neuropeptide Y5 antagonists
ATE405257T1 (en) 1999-11-26 2008-09-15 Shionogi & Co NPYY5 ANTAGONISTS
GB0010757D0 (en) 2000-05-05 2000-06-28 Astrazeneca Ab Chemical compounds
NZ526623A (en) * 2000-12-22 2004-11-26 Astrazeneca Ab Carbazole derivatives and their use as neuropeptide Y5 receptor ligands
DE10125961A1 (en) * 2001-05-29 2002-12-12 Boehringer Ingelheim Int Carbazole derivatives and their use in the manufacture of a pharmaceutical composition for the treatment of ailments related to NPY
GB0121941D0 (en) 2001-09-11 2001-10-31 Astrazeneca Ab Chemical compounds
DE10164564B4 (en) * 2001-12-14 2007-05-16 Zentaris Gmbh Tetrahydrocarbazole derivatives as ligands for G-protein coupled receptors (GPCR)
US7067549B2 (en) * 2001-12-31 2006-06-27 Actelion Pharmaceuticals Ag Pyrrolidone carboxamides
CA2471620A1 (en) * 2001-12-31 2003-07-24 Actelion Pharmaceuticals Ltd Pyrrolidone carboxamides
ES2193875B2 (en) 2002-04-09 2005-03-01 Laboratorios Del Dr. Esteve, S.A. DERIVATIVES OF BENZOXAZINONA, ITS PREPARATION AND ITS APPLICATION AS MEDICATIONS.
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
EP2426122A1 (en) * 2002-10-24 2012-03-07 Merck Patent GmbH Methylene urea derivative as RAF kinasse inhibitors
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7528151B2 (en) 2003-03-06 2009-05-05 Glaxo Group Limited Heterocyclic urea derivatives for the treatment of pain
WO2004078744A2 (en) 2003-03-07 2004-09-16 Glaxo Group Limited Urea derivatives and their use as vanilloid receptor antagonists in the treatment of pain
GB0305426D0 (en) 2003-03-08 2003-04-16 Glaxo Group Ltd Novel compounds
ES2222833B1 (en) 2003-07-30 2006-03-01 Laboratorios Del Dr. Esteve, S.A. 1,4-DISPOSED PIPERIDINIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICINES.
AU2004274309B2 (en) 2003-09-22 2010-04-08 Msd K.K. Novel piperidine derivative
EP1679296A4 (en) * 2003-10-14 2007-12-26 Ajinomoto Kk Ether derivative
US7365193B2 (en) 2004-02-04 2008-04-29 Abbott Laboratories Amino-substituted tricyclic derivatives and methods of use
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc Method of treating men with metabolic and anthropometric disorders
CN101083994A (en) 2004-09-20 2007-12-05 泽农医药公司 Heterocyclic derivatives and their use as therapeutic agents
TW200624427A (en) 2004-09-20 2006-07-16 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
BRPI0515488A (en) 2004-09-20 2008-07-29 Xenon Pharmaceuticals Inc heterocyclic derivatives and their use as therapeutic agents
BRPI0515482A (en) 2004-09-20 2008-07-22 Xenon Pharmaceuticals Inc heterocyclic derivatives and their uses as therapeutic agents
WO2006034338A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-coa desaturase
WO2006034315A2 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
US7829712B2 (en) 2004-09-20 2010-11-09 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase
EP2127676A3 (en) 2004-11-01 2013-09-04 Amylin Pharmaceuticals, LLC Treatment of obesity and related disorders
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
ITMI20050909A1 (en) 2005-05-19 2006-11-20 Acraf USE OF A BENZOIL DERIVED FROM 3-AMINO-CARBAZOLE FOR THE PRODUCTION OF A DRUG FOR THE TREATMENT OF A DISORDER ASSOCIATED WITH THE PRODUCTION OF PROSTAGLANDINA E2-PGE2-
US8138206B2 (en) 2005-05-30 2012-03-20 Msd. K.K. Piperidine derivative
BRPI0611187A2 (en) 2005-06-03 2010-08-24 Xenon Pharmaceuticals Inc amino thiazide derivatives as inhibitors of human stearoyl coa desaturase
ITMI20051523A1 (en) 2005-08-03 2007-02-04 Acraf COMPOUND OF 3-AMINO-CARBAZOLE PHARMACEUTICAL COMPOSITION THAT CONTAINS IT AND METHOD TO PREPARE IT
US20100216758A1 (en) 2005-08-10 2010-08-26 Makoto Ando Pyridone Compounds
EP2330125A3 (en) 2005-08-11 2012-12-12 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
EP1922336B1 (en) 2005-08-11 2012-11-21 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
DE602006017712D1 (en) 2005-08-24 2010-12-02 Banyu Pharma Co Ltd PHENYLPYRIDONDERIVAT
WO2007029847A1 (en) 2005-09-07 2007-03-15 Banyu Pharmaceutical Co., Ltd. Bicyclic aromatic substituted pyridone derivative
BRPI0616463A2 (en) 2005-09-29 2011-06-21 Merck & Co Inc compound, pharmaceutical composition, and use of a compound
BRPI0617621A2 (en) 2005-10-21 2011-08-02 Novartis Ag combination of organic compounds
JPWO2007049798A1 (en) 2005-10-27 2009-04-30 萬有製薬株式会社 New benzooxathiin derivatives
KR101318127B1 (en) 2005-11-10 2013-10-16 엠에스디 가부시키가이샤 Aza-substituted spiro derivative
US7935715B2 (en) * 2006-07-28 2011-05-03 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
EP2065369A4 (en) * 2006-08-23 2011-12-28 Astellas Pharma Inc Urea compound or salt thereof
WO2008039327A2 (en) 2006-09-22 2008-04-03 Merck & Co., Inc. Method of treatment using fatty acid synthesis inhibitors
US20090247560A1 (en) 2006-09-28 2009-10-01 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
US20090325956A1 (en) * 2006-10-13 2009-12-31 Takahiko Taniguchi Aromatic amine derivative and use thereof
CA2682727C (en) 2007-04-02 2016-03-22 Banyu Pharmaceutical Co., Ltd. Indoledione derivative
MX354786B (en) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER and OTHER DISORDERS.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US20110015181A1 (en) 2008-03-06 2011-01-20 Makoto Ando Alkylaminopyridine derivative
WO2009119726A1 (en) 2008-03-28 2009-10-01 萬有製薬株式会社 Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor
EP2119705A1 (en) 2008-05-14 2009-11-18 AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. 3-Aminocarbozole compound, pharmaceutical composition containing it and preparation method therefor
ES2627848T3 (en) 2008-06-04 2017-07-31 Synergy Pharmaceuticals Inc. Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8080566B1 (en) 2008-06-11 2011-12-20 Kalypsys, Inc Carbazole inhibitors of histamine receptors for the treatment of disease
AU2009261248A1 (en) 2008-06-19 2009-12-23 Banyu Pharmaceutical Co., Ltd. Spirodiamine-diarylketoxime derivative
ES2624828T3 (en) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer and others
EP2319841A1 (en) 2008-07-30 2011-05-11 Msd K.K. (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative
WO2010047982A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
PE20110852A1 (en) 2008-10-30 2011-11-25 Merck Sharp & Dohme ISONICOTINAMIDE OREXIN RECEPTOR ANTAGONISTS
AU2009309037A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010075069A1 (en) 2008-12-16 2010-07-01 Schering Corporation Bicyclic pyranone derivatives as nicotinic acid receptor agonists
US20110245209A1 (en) 2008-12-16 2011-10-06 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
WO2010080481A1 (en) 2008-12-19 2010-07-15 Bristol-Myers Squibb Company Carbazole carboxamide compounds useful as kinase inhibitors
CA2786314A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
MY159058A (en) 2011-02-25 2016-12-15 Merck Sharp & Dohme Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agent
AR088352A1 (en) 2011-10-19 2014-05-28 Merck Sharp & Dohme ANTAGONISTS OF THE RECEIVER OF 2-PIRIDILOXI-4-NITRILE OREXINE
RU2015106909A (en) 2012-08-02 2016-09-27 Мерк Шарп И Доум Корп. ANTI-DIABETIC TRICYCLIC COMPOUNDS
US9840512B2 (en) 2013-02-22 2017-12-12 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
US9486494B2 (en) 2013-03-15 2016-11-08 Synergy Pharmaceuticals, Inc. Compositions useful for the treatment of gastrointestinal disorders
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
KR102272746B1 (en) 2013-06-05 2021-07-08 보슈 헬스 아일랜드 리미티드 Ultra-pure agonists of guanylate cyclase c, method of making and using same
WO2015031914A1 (en) * 2013-08-30 2015-03-05 Uti Limited Partnership Store overload-induced calcium release inhibitors and methods for producing and using the same
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
TW201607943A (en) * 2013-12-19 2016-03-01 拜耳製藥公司 Novel benzimidazole derivatives as EP4 ligands
CA2959208C (en) 2014-08-29 2023-09-19 Tes Pharma S.R.L. Pyrimidine derivatives and their use as inhibitors of alpha-amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase
MA52119A (en) 2015-10-19 2018-08-29 Ncyte Corp HETEROCYCLIC COMPOUNDS USED AS IMMUNOMODULATORS
SG10202004618TA (en) 2015-11-19 2020-06-29 Incyte Corp Heterocyclic compounds as immunomodulators
MD3394033T2 (en) 2015-12-22 2021-04-30 Incyte Corp Heterocyclic compounds as immunomodulators
US20170320875A1 (en) 2016-05-06 2017-11-09 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2017205464A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
LT3472167T (en) 2016-06-20 2022-11-10 Incyte Corporation Heterocyclic compounds as immunomodulators
US20180016260A1 (en) 2016-07-14 2018-01-18 Incyte Corporation Heterocyclic compounds as immunomodulators
US20180057486A1 (en) 2016-08-29 2018-03-01 Incyte Corporation Heterocyclic compounds as immunomodulators
MX2019004321A (en) 2016-10-14 2019-06-12 Tes Pharma S R L Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase.
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
EP3558298A4 (en) 2016-12-20 2020-08-05 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
BR112019012993A2 (en) 2016-12-22 2019-12-03 Incyte Corp benzo-oxazole derivatives as immunomodulators
MA47120A (en) 2016-12-22 2021-04-28 Incyte Corp PYRIDINE DERIVATIVES USED AS IMMUNOMODULATORS
WO2018119236A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
US10729689B2 (en) * 2017-10-26 2020-08-04 University Of Puerto Rico Carbazole EHop-016 derivatives as anti-cancer and anti-migratory agents
LT3774791T (en) 2018-03-30 2023-04-11 Incyte Corporation Heterocyclic compounds as immunomodulators
HRP20230306T1 (en) 2018-05-11 2023-05-12 Incyte Corporation Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators
CN113302189A (en) 2018-11-20 2021-08-24 Tes制药有限责任公司 Inhibitors of alpha-amino-beta-carboxyadipimic acid semialdehyde decarboxylating enzyme
EP3924058A1 (en) 2019-02-13 2021-12-22 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists
WO2021026047A1 (en) 2019-08-08 2021-02-11 Merck Sharp & Dohme Corp. Heteroaryl pyrrolidine and piperidine orexin receptor agonists
WO2021030162A1 (en) 2019-08-09 2021-02-18 Incyte Corporation Salts of a pd-1/pd-l1 inhibitor
KR20220075382A (en) 2019-09-30 2022-06-08 인사이트 코포레이션 Pyrido[3,2-d]pyrimidine compounds as immunomodulators
MX2022005651A (en) 2019-11-11 2022-07-27 Incyte Corp Salts and crystalline forms of a pd-1/pd-l1 inhibitor.
US20230174485A1 (en) * 2020-03-25 2023-06-08 Sri International Lipoxygenase inhibitors
CN116249697A (en) 2020-08-18 2023-06-09 默沙东有限责任公司 Bicycloheptane pyrrolidine orexin receptor agonists
WO2022099075A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Crystalline form of a pd-1/pd-l1 inhibitor
WO2022099018A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Process of preparing a pd-1/pd-l1 inhibitor
AU2021373044A1 (en) 2020-11-06 2023-06-08 Incyte Corporation Process for making a pd-1/pd-l1 inhibitor and salts and crystalline forms thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0927166A1 (en) * 1997-02-14 1999-07-07 Bayer Corporation Amides as npy5 receptor antagonists
JP2000510164A (en) * 1997-02-14 2000-08-08 バイエル・コーポレーシヨン Amide derivatives as selective neuropeptide Y receptor antagonists

Also Published As

Publication number Publication date
WO2001007409A1 (en) 2001-02-01

Similar Documents

Publication Publication Date Title
AU6000900A (en) Carbazole derivatives and their use as neuropeptide y5 receptor ligands
IL156487A0 (en) Carbazole derivatives and their use as neuropeptide y5 receptor ligands
AU7314200A (en) Benzimidazole derivatives
EG23817A (en) 4-Phenyl-pyridine derivatives
AU6314900A (en) Biarylurea derivatives
AU6714700A (en) Cyclopropylindole derivatives
AU2929700A (en) Tong
IL149584A0 (en) New phenalkyloxy-phenyl derivatives
AU1734401A (en) Carboxyamido derivatives
AU5319700A (en) Nicotine receptor ligands
AU7952800A (en) 2-alkoxybenzene derivatives
AU3670000A (en) Novel thiazolobenzimidazole derivatives
AU5429000A (en) Novel bicyclonucleoside derivatives
HK1047049A1 (en) Indole derivatives
AU3289700A (en) Tetrahydropyridazine derivatives
AU5568400A (en) Novel dihydropyrimidine derivatives
HUP0202479A3 (en) Indole derivatives
IL150336A0 (en) Novel indole derivatives
AU6913100A (en) Notch receptor ligands and uses thereof
EG26101A (en) Ethanesulfonyl-piperidine derivatives
EP1229913A4 (en) Substituted 1-benzazepines and derivatives thereof
AP2001002327A0 (en) 1-Trifluoromethyl-4-hydroxy-7- piperidinylaminomethy lchroman derivatives
AU6262300A (en) Indolinylamide derivatives
AU1558300A (en) 1-cycloalkylpyrazoyl-benzoyl derivatives
AU5914200A (en) Amino-alkyl derivatives

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase